Figure 2From: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled studyEffect of six month therapy with trimetazidine or placebo on left ventricular ejection fraction (LVEF). A significant improvement in LVEF was detected in patients receiving trimetazidine while a decrease of LVEF was noted in patients allocated to standard care and placeboBack to article page